☆ 4.7 Review

Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review

JOURNAL OF MEDICAL VIROLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Cell Biology

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Pengfei Li et al.

CELL RESEARCH (2022)

添加到收藏夹

Review Cell Biology

Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design

Brandon Malone et al.

Summary: The molecular basis and complexity of coronavirus RNA-synthesizing machinery is still not fully understood. Recent research has focused on deciphering and understanding the structures, functions, and interactions of the subunits involved in SARS-CoV-2 replication and transcription. Both viral and host factors play a crucial role in coordinating RNA translation, replication, and transcription, making them potential targets for antiviral therapy.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Cell Biology

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

William A. Fischer et al.

Summary: In a clinical trial, the safety, tolerability, and antiviral efficacy of molnupiravir were evaluated in unvaccinated individuals with confirmed SARS-CoV-2 infection. The study found that participants receiving high-dose molnupiravir had a shorter time to viral RNA clearance and a lower detection rate of infectious virus. Molnupiravir was well tolerated across all doses.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Review Endocrinology & Metabolism

An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19

Awadhesh Kumar Singh et al.

Summary: Molnupiravir is an oral antiviral drug that has received emergency use authorization in the USA, UK, and India. Recent studies have shown that it can significantly reduce the risk of hospitalization or death in non-hospitalized COVID-19 patients. Molnupiravir is comparatively cheaper than other agents and can be an effective option for treating COVID-19, but it needs to be used within 5 days of symptom onset.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2022)

添加到收藏夹

Review Medicine, Research & Experimental

A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2

Alexander Simonis et al.

Summary: The COVID-19 pandemic has highlighted the urgent need for effective antiviral drugs, and repurposing existing drugs and compounds has shown some progress in treatment strategies, including the effectiveness of drugs like remdesivir.

EMBO MOLECULAR MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

A global survey of potential acceptance of a COVID-19 vaccine

Jeffrey V. Lazarus et al.

Summary: Survey data from 19 countries reveals varying attitudes towards acceptance of a COVID-19 vaccine, with trust in government being linked to vaccine confidence.

NATURE MEDICINE (2021)

添加到收藏夹

Article Chemistry, Organic

A Concise Route to MK-4482 (EIDD-2801) from Cytidine: Part 2

Vijayagopal Gopalsamuthiram et al.

Summary: A new synthesis route for MK-4482 has been developed, utilizing cytidine instead of uridine to improve yield and accessibility. It is expected to expand access to MK-4482 as a viable drug substance.

SYNLETT (2021)

添加到收藏夹

Article Microbiology

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Robert M. Cox et al.

Summary: Treating SARS-CoV-2-infected ferrets with nucleoside analogue MK-4482/EIDD-2801 reduced viral load and suppressed virus spread. This therapeutic approach shows promise in breaking transmission chains of the COVID-19 pandemic.

NATURE MICROBIOLOGY (2021)

添加到收藏夹

Article Microbiology

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

Wendy P. Painter et al.

Summary: Molnupiravir showed rapid appearance and dose-proportional increase in plasma, with good tolerability in healthy volunteers. The study evaluated single and multiple doses of molnupiravir and the impact of food on pharmacokinetics in subjects, showing no accumulation following multiple doses and a decrease in absorption rate when administered with food, but no decrease in overall exposure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Mohd Imran et al.

Summary: Molnupiravir, developed initially for influenza treatment, has shown promising activity against various viruses, including SARS-CoV-2. With good safety profile and oral bioavailability, it is currently in development for treating COVID-19 and expected to be available in an oral dosage form in 2022. Patent data suggests potential combinations with other drugs to enhance efficacy.

MOLECULES (2021)

添加到收藏夹

Correction Biochemistry & Molecular Biology

Molnupiravir: coding for catastrophe (Sep, 10.1038/s41594-021-00657-8, 2021)

Brandon Malone et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801

Angela Wahl et al.

Summary: The study suggests that bats may be the source of coronaviruses that can be directly transmitted to humans. Using the LoM model, efficient replication of SARS-CoV, MERS-CoV, SARS-CoV-2, and two SARS-like bat coronaviruses in human lung tissue was demonstrated. Infection with SARS-CoV-2 predominantly targets human lung epithelial cells and induces a sustained inflammatory response. The broad-spectrum antiviral agent EIDD-2801 significantly inhibits SARS-CoV-2 replication in vivo, showing potential for prevention and treatment of COVID-19.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP

Katerina Naydenova et al.

Summary: The structure of the RNA polymerase inhibitor favipiravir bound to the SARS-CoV-2 RNA-dependent RNA polymerase has been determined, revealing its binding mode at the catalytic site. The inhibitor is weakly incorporated into the RNA primer strand, leading to suppression of RNA replication in the presence of natural nucleotides.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Virology

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses

Yining Wang et al.

Summary: The study demonstrates that molnupiravir effectively inhibits the replication and production of infectious viruses of seasonal coronaviruses by targeting RNA-dependent RNA polymerase in cell culture models. Furthermore, when combined with the protease inhibitor GC376, it shows enhanced antiviral activity, highlighting its potential for treating patients infected with seasonal coronaviruses.

VIROLOGY (2021)

添加到收藏夹

Article Virology

Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections

Aleksandr Ianevski et al.

Summary: The study demonstrates that the combination of interferon alpha with various drugs can effectively inhibit the replication of SARS-CoV-2 and treat other viral infections at lower concentrations, showing promising potential for further pre-clinical and clinical development against emerging and re-emerging viral infections.

VIRUSES-BASEL (2021)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Letter Medicine, General & Internal

Buyer beware: molnupiravir may damage DNA

Johan M. van Schalkwyk

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Virology

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19

George R. Painter et al.

Summary: Although vaccines are available, there is still a critical need for antiviral drugs with potent activity against SARS-CoV-2, especially for immunosuppressed individuals and emerging variants. Molnupiravir evolved from preclinical development for influenza to a potential COVID-19 treatment, with the development timeline accelerated significantly to focus on coronavirus infections. Collaboration with regulatory authorities in real time played a key role in expediting the program.

CURRENT OPINION IN VIROLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Brief review on repurposed drugs and vaccines for possible treatment of COVID-19

Priyasha De et al.

Summary: This review discusses the impact of SARS-CoV-2 on human cellular metabolism, as well as research on antiviral drugs and drug targets. It evaluates the molecular mechanisms, combination therapies and possible alternatives of antiviral drugs, while also focusing on factors such as drug dosage and adverse reactions.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One

Philippine Eloy et al.

EBIOMEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

Rana Abdelnabi et al.

Summary: The combination of Molnupiravir and Favipiravir demonstrated a significant antiviral effect in a Syrian hamster model infected with SARS-CoV-2, reducing infectious virus titers in the lungs and preventing transmission to co-housed untreated sentinels. Mutation frequency in the viral RNA recovered from the lungs of treated animals increased, with a higher frequency of C-to-T mutations observed in the combo treatment group, explaining the pronounced antiviral potency of the combination.

EBIOMEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template

Calvin J. Gordon et al.

Summary: The study found that Molnupiravir or NHC can increase the mutation frequencies in replicating coronaviruses, leading to enhanced antiviral effects; NHC-TP primarily competes with CTP for incorporation, resulting in RNA mutations; Biochemical data support a mechanism of action of Molnupiravir that is primarily based on RNA mutagenesis mediated via the template strand.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

添加到收藏夹

Article Immunology

β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

Shuntai Zhou et al.

Summary: Mutagenic ribonucleosides can serve as broad-spectrum antiviral agents, but may pose risks to the host due to their host mutagenic activity in addition to antiviral activity.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Immunology

Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview

Ahmed A. Al-Karmalawy et al.

Summary: Respiratory viruses are a major public health concern due to their high mutation rate, with the newly emerging SARS-CoV-2 causing the COVID-19 pandemic globally. Continuous monitoring and updating of vaccines is needed to match the evolving variants of the virus.

VACCINES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex

Brandon Malone et al.

Summary: Backtracking, a common regulatory feature in transcription, is found in viruses as well, with evidence suggesting that SARS-CoV-2 RdRp may utilize backtracking for viral transcription and replication. The interaction between RdRp and nsp13 helicase facilitates backtracking, which may aid in proofreading and antiviral resistance for SARS-CoV-2.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Review Endocrinology & Metabolism

Molnupiravir in COVID-19: A systematic review of literature

Awadhesh Kumar Singh et al.

Summary: Molnupiravir has shown significant benefits in reducing hospitalization or death in mild COVID-19 cases, making it a potential important tool in combating SARSCoV-2. However, its efficacy in moderate to severe COVID-19 remains uncertain, requiring further studies for clarification.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Kyle Rosenke et al.

Summary: Orally administered nucleoside analog MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model, with an inhibitory effect observed whether the drug is given 12 hours before or 12 hours after infection. This suggests the potential of MK-4482 for controlling SARS-CoV-2 infection in humans following high-risk exposure and for treating COVID-19 patients.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight US Locations, December 2020-March 2021

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Infectious Diseases

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye H. Khoo et al.

Summary: The study found that molnupiravir is safe and well tolerated in treating early COVID-19 patients. A dose of 800mg twice daily for 5 days was recommended for Phase II evaluation.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

添加到收藏夹

Article Immunology

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model

Rana Abdelnabi et al.

Summary: The emergence of SARS-CoV-2 variants of concern has worsened the COVID-19 pandemic, with current monoclonal antibodies and vaccines showing reduced efficacy against some of these variants. However, antivirals targeting conserved proteins of SARS-CoV-2 are likely to remain effective. Research on molnupiravir has shown effectiveness against different variants, highlighting its potential in combating current and future variants.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

Florian Kabinger et al.

Summary: Molnupiravir is an oral antiviral drug candidate that increases viral RNA mutations frequency and inhibits replication of SARS-CoV-2 by altering the substrate preference of RdRp. This two-step mutagenesis mechanism can explain the broad-spectrum antiviral activity of molnupiravir, making it a promising COVID-19 treatment option.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2

Wendy Holman et al.

Summary: The article discusses the safety, tolerability, and pharmacokinetic profile of a novel antiviral agent, molnupiravir, and describes the accelerated collaboration that led to the rapid generation of phase I data in the United Kingdom. The study involved single and multiple ascending dose cohorts, as well as a food-effect cohort, which together allowed for efficient dosing in healthy volunteers within 16 weeks. The successful completion of this study supported the submission of a phase 2/3 clinical trial protocol to the FDA within 8 weeks, demonstrating an accelerated timeline in the context of a global pandemic without compromising safety.

TRIALS (2021)

添加到收藏夹

Article Microbiology

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

Agnieszka M. Szemiel et al.

Summary: This study selected drug-resistant SARS-CoV-2 populations with decreased sensitivity to remdesivir (RDV) in vitro, identifying a mutation in NSP12 that decreases RDV sensitivity. There is no evidence of widespread transmission of RDV-resistant mutants among globally circulating SARS-CoV-2 variants. Additionally, emerging SARS-CoV-2 variants showed substitutions at Spike sites corresponding to those identified in vitro, indicating their potential to arise without immune selection.

PLOS PATHOGENS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses

Matthew A. Schaller et al.

Summary: The researchers developed a system for ex vivo study of human SARS-CoV-2 infection using primary human lung tissue from a library of donor tissues. They found significant donor-dependent heterogeneity in the host response to SARS-CoV-2, and some drugs were effective in suppressing viral replication in the tissues.

JCI INSIGHT (2021)

添加到收藏夹

Article Microbiology

TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)

Jihye Lee et al.

Summary: The emergence of SARS-CoV-2 variants poses a threat to the efficacy of current vaccines and therapeutics, but drugs targeting TMPRSS2 and RdRp have been found to be effective against the new variants. This suggests that small-molecule inhibitors may be potent control measures against the COVID-19 pandemic.

MICROBIOLOGY SPECTRUM (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Calvin J. Gordon et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

添加到收藏夹

Review Medical Laboratory Technology

Next-generation direct-acting influenza therapeutics

Mart Toots et al.

TRANSLATIONAL RESEARCH (2020)

添加到收藏夹

Letter Infectious Diseases

Epidemiological characteristics and transmission model of Corona Virus Disease 2019 in China

Dongming Wang et al.

JOURNAL OF INFECTION (2020)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Rapid repurposing of drugs for COVID-19

R. Kiplin Guy et al.

SCIENCE (2020)

添加到收藏夹

Article Cell Biology

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

Coronavirus disease 2019 (COVID-19): A literature review

Harapan Harapan et al.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection

Zhonglei Wang et al.

FRONTIERS IN PHARMACOLOGY (2020)

添加到收藏夹

Letter Medicine, Research & Experimental

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

Gareth Griffiths et al.

TRIALS (2020)

添加到收藏夹

Article Virology

Potential Antiviral Options against SARS-CoV-2 Infection

Aleksandr Ianevski et al.

VIRUSES-BASEL (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial

Christoph D. Spinner et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Review Immunology

Mechanisms of SARS-CoV-2 Transmission and Pathogenesis

Andrew G. Harrison et al.

TRENDS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Virology

Identification and Tracking of Antiviral Drug Combinations

Aleksandr Ianevski et al.

VIRUSES-BASEL (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

FDA Approval of Remdesivir - A Step in the Right Direction

Daniel Rubin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Microbiology

A Structure-Function Diversity Survey of the RNA-Dependent RNA Polymerases From the Positive-Strand RNA Viruses

Hengxia Jia et al.

FRONTIERS IN MICROBIOLOGY (2019)

添加到收藏夹

Article Virology

Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

Maria L. Agostini et al.

JOURNAL OF VIROLOGY (2019)

添加到收藏夹

Article Cell Biology

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

Mart Toots et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Article Microbiology

Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses

Jeong-Joong Yoon et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

RNA 3′-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex

Mickael Bouvet et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

添加到收藏夹

Article Microbiology

Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture

LJ Stuyver et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.